Vaping-Related Lung Injury: New CDC Recommendations for Primary Care Physicians

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Your daily dose of the clinical news you may have missed.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.